Adds details throughout

May 26 (Reuters) - Cardiovascular drug developer Kardigan on Tuesday filed for an initial public offering in the United States.

A rebound in biotech IPO issuance signals improving risk appetite in equity markets, as investors return to healthcare companies with advanced-stage drug pipelines and clearer paths toward commercialization.

Kardigan is a U.S.-based clinical-stage biotechnology company developing precision medicines for cardiovascular diseases. The company is advancing three late-stage experimental therapies.

Kardigan will list on the Nasdaq Global Market under the ticker symbol "KARD".

J.P. Morgan, Jefferies, Leerink Partners and TD Cowen are the underwriters for the offering.